Skip to main content

What Dexcom's Quarter ended Sep 30, 2026 10-Q says: 1 signal

Dexcom filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses inventory issue.

Public (DXCM)Medical Equipment Manufacturing10,000+ employeesdexcom.comLinkedIn

Get Dexcom's live signals in Claude or ChatGPT, or by API

AskWhat changed at Dexcom this week? Use Autobound signals for dexcom.com.
Filed
Oct 29, 2026
Period
Quarter ended Sep 30, 2026
Filings
2
Signals
2

Source: Autobound Signal API · 83 signals tracked for Dexcom · updated

10-Q · latest 2

What Dexcom's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 1 signal

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 1 signal

    SEC EDGAR

Earnings calls

Dexcom earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Worldwide revenue up 11% to $1.34B in Q3Worldwide revenue reached $1.34 billion, growing 11% reported and organic year-over-year. U.S. revenue totaled $970 million, up 14%, while international revenue generated $375 million with 5% growth. Gross margin improved 380 basis points to 65.1%, and operating margin expanded to 25.3%.
Full-year revenue guidance raised to $5.20B to $5.25BFull-year 2026 revenue guidance was raised to a range of $5.20 billion to $5.25 billion, representing 12% to 13% growth. Management also increased non-GAAP operating margin guidance to approximately 24% and adjusted EBITDA margin to approximately 32%, while maintaining gross margin guidance at approximately 64%.
Signed deal to acquire European distributor businessA deal was signed to acquire the business of its largest remaining distributor partner in Europe to transition to direct operations across high-potential European markets. The transaction is in the sign-to-close phase and is expected to close in 2027 with no financial impact in Q3 or Q4 2026.
Redesigned Stelo app and international G7 rolloutA fully redesigned Stelo app was launched in Q3 featuring enhanced glucose insights, meal logging, and nutritional data. Internationally, the G7 15 Day system will officially launch in Canada in November 2026 following Health Canada clearance, with a launch in Japan planned for early 2027.
Captured U.S. market share led by type 2 non-insulinMarket share was captured across the U.S. CGM market, driven by customers with type 2 diabetes not on insulin. Global new patient starts reached near-record levels in Q3, supporting upper-teens active base growth ahead of an anticipated Medicare type 2 non-insulin coverage decision.
Commercial production initiated at Ireland manufacturing plantCommercial production was initiated on schedule at the manufacturing plant in Ireland, expanding global manufacturing capacity across Europe alongside existing plants in the U.S. and Asia Pacific. The facility startup is expected to cause a temporary overhead variance drag on gross margin in Q4 and early 2027 before volume ramps up.

Signal API · MCP

Track Dexcom with the Signal API

One POST /v1/companies/enrich call with dexcom.com returns Dexcom 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"dexcom.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Dexcom 10-Q

When did Dexcom file its latest 10-Q?
Dexcom filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 29, 2026. The one before it was filed on Jul 30, 2026.
What did Dexcom disclose in its latest 10-Q?
From the filing dated Oct 29, 2026: Higher inventory reserve charges incurred from planned discontinuation of G6 manufacturing
What did Dexcom say on its recent earnings calls?
Q3 FY2026: Worldwide revenue up 11% to $1.34B in Q3 (dated Oct 29, 2026).
Where can I read Dexcom's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1093557/000109355726000195/dxcm-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →